Last reviewed · How we verify

NovoMix® 30 Penfill®

Geropharm · Phase 1 active Small molecule

NovoMix® 30 Penfill® is a Small molecule drug developed by Geropharm. It is currently in Phase 1 development. Also known as: biphasic insulin aspart 30.

At a glance

Generic nameNovoMix® 30 Penfill®
Also known asbiphasic insulin aspart 30
SponsorGeropharm
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about NovoMix® 30 Penfill®

What is NovoMix® 30 Penfill®?

NovoMix® 30 Penfill® is a Small molecule drug developed by Geropharm.

Who makes NovoMix® 30 Penfill®?

NovoMix® 30 Penfill® is developed by Geropharm (see full Geropharm pipeline at /company/geropharm).

Is NovoMix® 30 Penfill® also known as anything else?

NovoMix® 30 Penfill® is also known as biphasic insulin aspart 30.

What development phase is NovoMix® 30 Penfill® in?

NovoMix® 30 Penfill® is in Phase 1.

Related